Traws Pharma (TRAW) late Friday said Werner Cautreels will retire as chief executive officer after the biopharmaceutical company completes and files its 2024 annual report, expected by Monday.
Cautreels will be succeeded on an interim basis by Iain D. Dukes, Traws board chair. Dukes will continue as board chair.
Cautreels also will remain a member of the Traws board and work as a special adviser at the company over the next 12 months, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.